This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Commitment to this study spans 24 days: 7 days of baseline, 10 days of a study assignment (exercise deprivation, sleep restriction, both, or nothing), and 7 days follow-up. To evaluate sleep/activity patterns, participants will wear an activity monitor for the duration of the study. It will prompt them to rate pain, fatigue and mood 3x throughout each day. For three days (3x/day) during baseline and following deprivation, subjects will collect saliva, using specifically designed kits. For one of these days, participants will wear a Holter (heart rate) monitor. To evaluate the influence of aerobic capacity on symptom development, participants will undergo a treadmill test at baseline, and at the end of their study assignment. Additionally, participants will complete self-report questionnaires, undergo several standardized cognitive (memory) tasks, and a pressure pain assessment. The population for this study includes healthy runners from Ann Arbor, MI and vicinity. All ethnic groups are eligible to participate, although the local population is predominately Caucasian, with equal male/female representation. Participants will be recruited via advertisements distributed among local running stores/clubs, gyms, and newspapers. Each of four study groups will contain 32 subjects with roughly equal numbers of males and females in each cell, for a total of 128 subjects. Once in the study, participants will be randomized: sleep deprivation, exercise deprivation, sleep+exercise deprivation, or normal activity. Identifying information will not be stored in the study databases, but will be housed in a secure data file on a limited access, non-networked, password-protected workstation. Prior to any data collection, participants will undergo an informed consent interview with a nurse practitioner. Participants will be given a copy of the consent document and ample time to read it, a verbal explanation of the protocol, and an opportunity to ask questions. Participants will then be asked to sign the informed consent document. An employee of UMHS with no direct involvement in the study will witness the signing of two copies of the informed consent document, one each for the participant and the study file. This file will be secured in a double-locked setting within the UMHS.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
2M01RR000042-46
Application #
7376548
Study Section
Special Emphasis Panel (ZRR1-CR-8 (02))
Project Start
2006-04-05
Project End
2007-02-28
Budget Start
2006-04-05
Budget End
2007-02-28
Support Year
46
Fiscal Year
2006
Total Cost
$31,681
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Robarge, Jason D; Desta, Zereunesay; Nguyen, Anne T et al. (2017) Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast Cancer Res Treat 161:453-461
Crane, Natania A; Jenkins, Lisanne M; Bhaumik, Runa et al. (2017) Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI. Brain 140:472-486
Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668
Hertz, D L; Kidwell, K M; Seewald, N J et al. (2017) Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. Pharmacogenomics J 17:521-527
Kadakia, Kunal C; Kidwell, Kelley M; Seewald, Nicholas J et al. (2017) Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. Breast Cancer Res Treat 164:411-419
Spengler, Erin K; Kleiner, David E; Fontana, Robert J (2017) Vemurafenib-induced granulomatous hepatitis. Hepatology 65:745-748
Heidemann, Lauren; Law, James; Fontana, Robert J (2017) A Text Searching Tool to Identify Patients with Idiosyncratic Drug-Induced Liver Injury. Dig Dis Sci 62:615-625
Kadakia, Kunal C; Snyder, Claire F; Kidwell, Kelley M et al. (2016) Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer. Oncologist 21:539-46
Ricker, Charité; Culver, Julie O; Lowstuter, Katrina et al. (2016) Increased yield of actionable mutations using multi-gene panels to assess hereditary cancer susceptibility in an ethnically diverse clinical cohort. Cancer Genet 209:130-7
Law, Ian H; Alam, Osman; Bove, Edward L et al. (2016) Follow-Up of a Prospective Surgical Strategy to Prevent Intra-Atrial Reentrant Tachycardia After the Fontan Operation. Circ Arrhythm Electrophysiol 9:

Showing the most recent 10 out of 1380 publications